The purpose of this study is to learn about how much the study medicine PF-07976016 will be taken up and processed by healthy male participants. The total number of weeks of the study is up to approximately 12 weeks.

Inclusion Criteria:

• Males, 18 to 65 years of age
• BMI 17.5 to 32 kg/m2 and a total body weight >50 kg (110 lb)
• Willing and able to comply with all study procedures

Exclusion Criteria:

• History of irregular bowel movements or lactose intolerance
• Any medical or psychiatric condition or laboratory abnormality or other condition that may increase the risk of study participation
• Use of any prohibited or concomitant medication(s)
• Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests
• Positive urine drug test
• History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence
• Use of tobacco/nicotine containing products in excess of the equivalent of 5 cigarettes/day
• Previous administration of an investigational product within 30 days preceding the first dose of study medicine in this study.

Healthy male participants

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.